Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

710 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Breast cancer: a candidate gene approach across the estrogen metabolic pathway.
Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, Rabstein S, Selinski S, Mueller T, Ickstadt K, Gilbert M, Ko YD, Baisch C, Pesch B, Harth V, Bolt HM, Vollmert C, Illig T, Eils R, Dippon J, Brauch H. Justenhoven C, et al. Among authors: illig t. Breast Cancer Res Treat. 2008 Mar;108(1):137-49. doi: 10.1007/s10549-007-9586-8. Epub 2007 Jun 23. Breast Cancer Res Treat. 2008. PMID: 17588204
The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer.
Justenhoven C, Pierl CB, Haas S, Fischer HP, Baisch C, Hamann U, Harth V, Pesch B, Brüning T, Vollmert C, Illig T, Dippon J, Ko YD, Brauch H. Justenhoven C, et al. Among authors: illig t. Breast Cancer Res Treat. 2008 Sep;111(1):171-7. doi: 10.1007/s10549-007-9762-x. Epub 2007 Oct 6. Breast Cancer Res Treat. 2008. PMID: 17922187
A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication.
Hein R, Flesch-Janys D, Dahmen N, Beckmann L, Lindström S, Schoof N, Czene K, Mittelstraß K, Illig T, Seibold P, Behrens S, Humphreys K, Li J, Liu J, Olson JE, Wang X, Hankinson SE, Truong T, Menegaux F, Dos Santos Silva I, Johnson N; GENICA Network; Chen ST, Yu JC, Ziogas A, Kataja V, Kosma VM, Mannermaa A, Anton-Culver H, Shen CY, Brauch H, Peto J, Guénel P, Kraft P, Couch FJ, Easton DF, Hall P, Chang-Claude J. Hein R, et al. Among authors: illig t. Breast Cancer Res Treat. 2013 Apr;138(2):529-542. doi: 10.1007/s10549-013-2443-z. Epub 2013 Feb 20. Breast Cancer Res Treat. 2013. PMID: 23423446 Free PMC article.
One-carbon metabolism and breast cancer risk: no association of MTHFR, MTR, and TYMS polymorphisms in the GENICA study from Germany.
Justenhoven C, Hamann U, Pierl CB, Rabstein S, Pesch B, Harth V, Baisch C, Vollmert C, Illig T, Brüning T, Ko Y, Brauch H. Justenhoven C, et al. Among authors: illig t. Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):3015-8. doi: 10.1158/1055-9965.EPI-05-0592. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 16365030 No abstract available.
Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer.
Jaremko M, Justenhoven C, Schroth W, Abraham BK, Fritz P, Vollmert C, Illig T, Simon W, Schwab M, Brauch H. Jaremko M, et al. Among authors: illig t. Pharmacogenet Genomics. 2007 Jul;17(7):529-38. doi: 10.1097/FPC.0b013e32801233fc. Pharmacogenet Genomics. 2007. PMID: 17558308
710 results